Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatm... SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.11 | -9.01639344262 | 1.22 | 1.25 | 1.07 | 239874 | 1.13841737 | CS |
| 4 | -0.05 | -4.31034482759 | 1.16 | 1.4 | 1.07 | 170653 | 1.20873811 | CS |
| 12 | -0.38 | -25.5033557047 | 1.49 | 1.62 | 1.07 | 152162 | 1.33395025 | CS |
| 26 | -0.89 | -44.5 | 2 | 2.29 | 1.07 | 147955 | 1.56155338 | CS |
| 52 | -0.53 | -32.3170731707 | 1.64 | 3.07 | 1.07 | 190846 | 1.78814089 | CS |
| 156 | -5.86 | -84.0746054519 | 6.97 | 7.58 | 1.07 | 354997 | 2.70024713 | CS |
| 260 | 0.369 | 49.7975708502 | 0.741 | 11.3 | 0.5 | 446022 | 3.31390946 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
